Biotech Startups

Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.

1 investor

OriGene develops and manufactures research and diagnostic products, including large-scale GMP antibody production, with R&D and research manufacturing operations. It serves the life sciences and biotech research market from facilities in the US and Germany.

1 investor

Origin by Ocean harvests invasive algae blooms to create bio-based ingredients for cosmetics, food, and textile industries through a proprietary biorefining process. The company addresses ocean pollution and ecosystem degradation while producing sustainable, regenerative materials.

1 investor

Origin Endoscopy has developed a multipurpose hydrogel designed for rapid bio-adhesion and submucosal injection applications in endoscopy. The technology targets surgical and medical procedure workflows that require biocompatible materials.

1 investor

Orion Biotechnology is a biotech company developing GPCR-targeted therapeutics for obesity and metabolic disorders, with preclinical candidates against targets including GPR75, GIPR, and amylin. It operates a proprietary drug discovery platform designed to shorten GPCR discovery campaigns and pursues out-licensing and R&D collaborations.

1 investor

Orio Therapeutics develops protein-based therapeutics using a technology that modifies therapeutic proteins with a built-in delivery system to control their localization at the injection site, improving efficacy and reducing dosage in regenerative medicine. Its first application is a molecule to protect cardiac muscle following a heart attack (myocardial infarction) by reducing fibrosis and cellular death.

1 investor

Orogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.

1 investor

Orphalan develops and commercializes innovative therapies for patients with rare diseases, with a focus on unmet medical needs where current treatments are limited or absent. The company has successfully brought trientine tetrahydrochloride (Cuprior®/Cuvrior®) to market for Wilson disease treatment across 30+ countries.

1 investor

ORSERDU (elacestrant) is a prescription oral medication for treating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in postmenopausal women and adult men whose disease has progressed after endocrine therapy. The product page is intended for US residents.

1 investor

Ortho BioMed combines expertise in medicine, engineering, and data science to develop medical technology solutions that improve patient outcomes.

1 investor

Abyrx (Orthocon) develops a materials science platform focused on therapeutic surgical devices, including water-soluble, resorbable hemostatic bone putty products such as MONTAGE. Its products are used by surgeons in orthopedic, trauma, spine, sports medicine, cranial, maxillofacial, and cardiothoracic procedures.

1 investor

Orvida Pharma develops pharmaceuticals for rare genetic skin diseases and orphan indications, with expertise spanning drug development from early discovery through FDA and EMA regulatory approval.

1 investor

Oryzon is a public clinical-stage biopharmaceutical company that uses epigenetics to discover and develop personalized therapies for patients with cancer and central nervous system (CNS) disorders. Its platform identifies and validates biomarkers and therapeutic targets to translate into drug candidates such as vafidemstat and iadademstat.

1 investor

OS Therapies (OST) is a clinical-stage cancer immunotherapy company developing treatments that activate the immune system to target HER2-expressing cancers, initially focusing on osteosarcoma in children and adults. It plans to expand its lead candidate into breast, colorectal, esophageal, lung, ovarian, and pancreatic cancers and other solid tumors.

1 investor

Osivax develops vaccines targeting conserved internal viral structures to provide broader and longer-lasting protection against influenza, leveraging its proprietary oligoDOM technology platform. The company originated from research co-developed with the University of Oxford and is supported by public health foundations and pharmaceutical partners.

1 investor

Osmol Therapeutics is a preclinical-stage biotech developing OSM-0205, an intravenous drug intended to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) in cancer patients receiving taxane-based therapy. The drug targets the interaction that triggers a calcium surge leading to neuronal damage, aiming to allow optimal chemotherapy dosing.

1 investor

OssDsign develops orthopedic and spine medical devices, drawing on expertise across clinical affairs, sales, and manufacturing from leading companies like Medtronic and Boston Scientific. The company serves surgical and orthobiologic markets with a team of executives experienced in bone healing and medical device commercialization.

1 investor

Ossianix develops TXP1, a brain-selective shuttle based on a deimmunised VNAR antibody scaffold that targets TfR1 to carry therapeutic payloads across the blood-brain barrier. The company focuses on improving delivery of central nervous system therapeutics to the brain.

1 investor

Developer of VT-X7 for the treatment of periprosthetic joint infection.

1 investor

Osteal Therapeutics is a clinical-stage pharmaceutical company developing novel treatments for orthopedic infections, particularly periprosthetic joint infections. Its lead product, NEXCHANGE KIT, is a drug-device combination designed for localized antibiotic delivery to infected joint prostheses.

1 investor

Osteocentric develops orthopedic implant systems for bone fixation, including fasteners, plates, and surgical instruments that use UnifiMI mechanical integration technology. The company serves orthopedic surgeons and hospitals treating fractures and skeletal injuries.

1 investor

Oticara is a clinical-stage biopharmaceutical company developing an investigational intranasal corticosteroid therapy for chronic rhinosinusitis (CRS). Its product is a single-dose, semisolid emulsion formulation placed by an ENT physician under endoscopic guidance, targeting patients with persistent symptoms after topical therapies and sinus surgery.

1 investor

OTIF Ventures is a venture capital firm that identifies and invests in high-quality technology and life science spinouts, particularly from Oxford University, providing ongoing board-level support to portfolio companies.

1 investor

OTOFARMA is an Italian manufacturer of custom hearing aids with ISO certification, sold exclusively through partnered pharmacies. The company also offers telemedicine audiology services, positioning itself as Italy's only certified hearing aid constructor with integrated remote consultations available in over 3,000 affiliated pharmacies.

1 investor